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A B S T R A C T
Objectives: The aim was to characterise age- and sex-specific severe acute respiratory syndrome
coronavirus disease-2 (SARS-CoV-2) RT-PCR sampling frequency and positivity rate in Greater Helsinki
area in Finland during February–June 2020. We also describe the laboratory capacity building for these
diagnostics.
Methods: Laboratory registry data for altogether 80,791 specimens from 70,517 individuals was analysed.
The data included the date of sampling, sex, age and the SARS-CoV-2 RT-PCR test result on specimens
collected between 1 February and 15 June 2020.
Results: Altogether, 4057/80,791 (5.0%) of the specimens were positive and 3915/70,517 (5.6%) of the
individuals were found positive. In all, 37% of specimens were from male and 67% from female subjects.
While the number of positive cases was similar in male and female subjects, the positivity rate was
significantly higher in male subjects: 7.5% of male and 4.4% of female subjects tested positive. The highest
incidence/100,000 was observed in those aged 80 years. The proportion of young adults in positive
cases increased in late May 2020. Large dips in testing frequency were observed during every weekend
and also during public holidays.
Conclusions: Our data suggest that men pursue SARS-CoV-2 testing less frequently than women.
Consequently, a subset of coronavirus disease-2019 infections in men may have gone undetected. People
sought testing less frequently on weekends and public holidays, and this may also lead to missing of
positive cases. The proportion of young adults in positive cases increased towards the end of the study
period, which may suggest their returning back to social behaviour with an increased risk of infection.
© 2020 The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).
The WHO has advocated for the ‘test, trace, treat’ strategy in the
mitigation of coronavirus disease-2019 (COVID-19) pandemic
(WHO, 2020). Rarely has sophisticated laboratory diagnostics
been set up at this pace and extent. As the epidemiological
situation evolved quickly, the laboratory capacity building over the
first few months played a key role in the epidemic response in each
country. At the same time, laboratory-based surveillance can
provide high quality data for public health management. By using
laboratory registry data, the aim of this study was to characterise
age- and sex-specific sampling frequency and positivity rate and to
characterise laboratory capacity building of severe acute respira-
tory syndrome coronavirus disease-2 (SARS-CoV-2) RT-PCR testing
in the Greater Helsinki area in Finland during February–June 2020.
Materials and methods
The study was conducted at the Helsinki University Hospital
Laboratory (HUS Diagnostic Center, HUSLAB), Finland, according to
research permit HUS/157/2020 (Helsinki University Hospital,
Finland).
Registry data
Contents lists available at ScienceDirect
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H. Jarva, M. Lappalainen, O. Luomala et al. International Journal of Infectious Diseases 104 (2021) 111–116rovides services to primary care and hospitals of Greater Helsinki,
ith a population of 1,685,983 (48.8% male and 51.2% female
ubjects; see Table 1 for age distribution) as per 31 December 2019
Official Statistics of Finland, 2020).
The data included the date of sampling, sex, age, and the SARS-
oV-2 RT-PCR test result on specimens from 1 February to 15 June
020. The data were collected according to permit HUS/157/2020
Helsinki University Hospital, Finland). The data were analysed
ith GraphPad Prism1 according to tests and individual cases. In
he case analysis, only the first test of the negative cases was
ounted. For the positive cases, only the first positive test was
ounted.
Data from the National Infectious Disease Register of the
ational Institute for Health and Welfare (THL) were retrieved to
alculate age-specific incidence.
aboratory methods
The respiratory specimens were subjected to one of the
ollowing methods (gene targets): a protocol based on Corman
t al. (N) (Corman et al., 2020), cobas1 SARS-CoV-2 test kit on the
obas1 6800 system (orf1ab and E) (Roche Diagnostics, Basel,
witzerland), Amplidiag1 COVID-19 test (orf1ab and N) (Mobidiag,
spoo, Finland) and Mobidiag Novodiag1 Covid-19 assay (orf1ab
nd N) (Mobidiag, Espoo, Finland). The performance of these tests
n our laboratory is reported elsewhere (Jokela et al., 2020;
annonen et al., 2021).
esting criteria
The testing criteria evolved during the study period. Until mid-
arch 2020, only symptomatic individuals with travel history to
pidemic areas or contact with a laboratory -confirmed COVID-19
ases and those admitted to the ICU were tested. As of 15 March,
ymptomatic patients who were either admitted to hospital; over
he age of 70; had a possible exposure or were nursing home
esidents were tested. A week later, symptomatic healthcare
orkers were included. As of 13 April, all symptomatic individuals
nd hospitalised risk group patients were tested.
esults
Of the 86,927 specimens sent to Helsinki University Hospital
aboratory (HUSLAB) for SARS-CoV-2 RT-PCR testing between 1
ebruary and 15 June, 5061 were excluded as they originated
utside of Greater Helsinki. Additional 1075 specimens were
xcluded as they repeatedly gave an invalid test result or were
ever analysed due to a preanalytical failure. The final data
ncluded 80,791 specimens (Figure 1a) from 70,517 individuals.
he tested individuals had a median age of 43 years, mean 45 years
nd a range of 0 days–106 years. Table 1 outlines the age
istribution of the tested individuals and the test-positive
individuals. Altogether, 4057/80,791 (5.0%) of the specimens were
positive and 3915/70,517 (5.6%) of the individuals were found
positive. The positive cases had a median age of 43 years, mean 45
years and range 0–100 years.
The first positive case in Greater Helsinki was diagnosed on 25
February (Figure 1a). This was the second COVID-19 case
diagnosed in Finland, the first being a Chinese tourist in Lapland
(Haveri et al., 2020). As of 9 March, both the number of tests,
positive tests and cases increased rapidly (Figure 1). A peak was
reached on 3 April (96 new cases) (Figure 1b), and the daily
number of new cases remained high throughout April and early
May.
During the epidemic peak, the daily number of tests was still
increasing through rapid capacity building. The daily number of
tests (by sampling date) increased from 308 tests on March 15 to
1005 tests on April 15, and further to 1530 tests on May 15
(Figure 1a). The positivity rate of the tests remained >10% until
early May 2020 (Figure 1a).
The highest proportion of positive cases was found in the age
group 50–59 years (6.7%) and the lowest in the age group 0–9 years
(2.9%) (Figure 2a). The number of test-positive cases was highest in
working-age adults (20–59 years) (Figure 2b). The age stratifica-
tion of new positive cases over time showed a shift towards an
increasing proportion of young adults (20–39 years) as of late May
(Figure 2c). The incidence per 100,000 population in the Greater
Helsinki area was 287/100,000 population and highest in those
aged 80 years (560/100,000) (Figure 2b).
In the age group 0–29 years, the proportion of test-positive
cases peaked during the weeks 13–15, while in the age group 30–
79 years, the highest proportions were observed already in weeks
11 and 12 (Figure 3). In those aged 80 years, the proportion of
positive cases began to increase in week 13 and peaked in week 15
(Figure 3).
Of the 80,791 specimens included in the study, 29,885
specimens were from 25,948 (36.8%) individual males and
50,906 specimens from 44,569 (63.2%) individual females. In
contrast, of the positive cases, 1935/3915 (49.4%) were male and
1980/3915 (50.6%) were female subjects. Thus, 7.5% (1935/25,948)
of male and 4.4% (1980/44,569) of female subjects tested were
positive. There was a statistically significant difference in these
proportions (z = 16.8595 and p < 0.01, calculated with Z-test). The
difference appeared to decrease towards the end of the study
period (Figure 4).
Discussion
By 30 June 2020, 80.2% of all tests performed and 77.3% of new
positive cases detected within the Hospital District of Helsinki and
Uusimaa were analysed in HUSLAB (THL, 2020), rendering our
surveillance data representative of Greater Helsinki. In Finland,
COVID-19 has mostly affected the Greater Helsinki area, which
represents 30% of the Finnish population (Official Statistics of
able 1
ge distribution of the population in Greater Helsinki, Finland; the study population and the SARS-CoV-2 RT-PCR test-positive population (Official Statistics of Finland, 2020).






0–9 10.8 6.7 3.6
10–19 10.9 6.0 6.2
20–29 13.4 14.9 16.0
30–39 15.3 17.4 18.0
40–49 13.4 15.1 15.4
50–59 13.1 13.6 16.4
60–69 10.7 9.2 8.9
70–79 8.4 8.6 5.9
80 4.1 8.5 9.7
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end of June 2020, have been detected in Greater Helsinki (THL,
2020).
The number of test-positive cases was similar in male and
female subjects, but the positivity rate in males was significantly
higher than in females. This may, to a small degree, be explained by
the overrepresentation of healthcare workers and female predom-
inance in the elderly. However, our data suggest that men pursued
SARS-CoV-2 testing much less frequently than women. Conse-
quently, a subset of COVID-19 infections in men may have gone
undetected. Abundant evidence shows that women generally seek
more healthcare services than men (Deveugele et al., 2002;
Thompson et al., 2016).
As of 18 March, several restrictions were implemented in
Finland. Schools were closed; public gatherings were restricted to
10 people; museums, theatres, libraries and public sports
facilities were closed; visits to nursing homes were forbidden
and public sector employees switched to remote work whenever
possible. As of 4 April, restaurants were also closed. Schools were
reopened on 14 May and restaurants and museums on 1 June
(with certain prerequisites) (Prime Minister’s Office, 2020). The
proportion of young adults who tested positive appeared to
The high incidence rate observed in the elderly is in line with
earlier reports (Natale et al., 2020). Vigilance in the infection
control in long-term care facilities remains critically important in
the mitigation of the pandemic.
Regarding limitations, our data did not include all tests analysed
in Greater Helsinki. No clinical data were available. A bias may have
been introduced by the restricted sampling criteria during March
2020. During the first weeks, control swabs were recommended for
the positive cases — a policy since abandoned. Furthermore, during
the first two weeks of April, less preferred oropharyngeal swabs
were used due to the global shortage of nasopharyngeal swabs,
which may have temporarily influenced the overall test sensitivity.
Large dips in testing frequency were observed on every
weekend and also during public holidays (Figure 1). Simulta-
neously, the number of new positive cases dropped each time, and
the epicurve (Figure 1b) may suggest that this testing deficit was
not fully compensated during the following weekdays.
In a response to need for large-scale testing, HUSLAB switched
from two-shift work into three-shift work on 23 March, and
personnel were reallocated. Following a rapid training period,
personnel from other laboratories were allocated for SARS-CoV-2
analytical testing. A laboratory-developed test (Corman et al.,
Figure 1. Number of SARS-CoV-2 RT-PCR tests and positive cases. (A) The number of SARS-CoV-2 RT-PCR tests conducted in HUSLAB by date of sampling and positivity rate,
between 1 March and 15 June 2020. (B) The number of SARS-CoV-2 positive cases (columns) with seven-day central moving average (line) by the date of sampling, between 1
March and 15 June 2020.increase towards the end of the study period, which may suggest
their returning back to social behaviour with risk of infection.
However, considering the incubation period (Lauer et al., 2020), it
does not appear likely that relaxing restrictions played a role with
this observation. Extension of testing criteria into mild symptoms
may have also contributed.1132020) was ready for use in mid-January and testing on the Cobas1
6800 system in late March. Because of constant global shortages of
reagents and plasticware, the need to deploy several independent
methods was evident to secure laboratory services and capacity
building. The Amplidiag1 COVID-19 tests were deployed as of mid-
April and the Novodiag1 sample-to-answer test as of mid-May.
Figure 2. Age characteristics of SARS-CoV-2 RT-PCR tested cases. (A) The number of individuals tested for SARS-CoV-2 RT-PCR by age group (columns) and the proportion of
SARS-CoV-2 positive cases (line). (B) The number of SARS-CoV-2 positive cases by age group and the age-specific incidence/100,000 population of SARS-CoV-2 in the Greater
Helsinki area (line), data from the National Infectious Diseases Registry. (C) Age stratification of SARS-CoV-2 positive cases by calendar week of 2020. The proportion (%) of
each age group is shown.
Figure 3. Age-specific number of SARS-CoV-2 RT-PCR tests and positive cases according to calendar week. (A–C) The age-specific number of individuals tested for SARS-CoV-
2 RT-PCR by calendar week of 2020. (D–F) The age-specific number of SARS-CoV-2-positive cases by calendar week of 2020. (G–I) The age-specific proportion (%) of SARS-CoV-
2-positive cases by calendar week of 2020. The age range for all tested male subjects was 1 d–102 years (mean 43.1 and median 41 years) and for positive male subjects 2
months–97 years (mean 43.5 and median 41 years). The age range for all tested female subjects was 0 d–106 years (mean 45.5 and median 43 years) and for positive female
subjects was 1 month–100 years (mean 47.7 and median 45 years).
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19 pandemic, the difference in healthcare seeking behaviours
between men and women needs to be accounted for to facilitate
high universal testing frequency. This is particularly relevant as
men are at higher risk of fatal infection and more likely to be
hospitalised and admitted to intensive care units due to COVID-19
(Garg et al., 2020; Grasselli et al., 2020; Mikami et al., 2020; Yu
et al., 2020). In addition, advocating and maintaining social
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